MGI To File Saforis NDA For Oral Mucositis By October
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to file the fast-track NDA based on the results of one Phase III trial. A second trial will be initiated after the filing in order to expand the market potential and support a European filing, MGI says.